InSightec will be on site at the RSNA annual meeting Nov. 30 to Dec. 5 to present its MR-guided Focused Ultrasound solution for ablation of uterine fibroids and alleviation of pain caused by bone metastases.

According to the company, its noninvasive therapeutic technology is “at the forefront of re-purposing the MRI suite from a purely diagnostic platform into a tool for delivering advanced care to patients in an ambulatory setting.”

InSightec representatives will be available to discuss the recent announcement made by the Health Care Service Corporation (HCSC) to include coverage of InSightec’s solution for pain palliation of bone metastases, opening the door to many patients who suffer from metastatic bone disease and have not responded to, or have rejected, radiation therapy.